Lupin 2023

Caret Pharma to buy Moberg’s Fiber Choice brand

Print Friendly, PDF & Email

BOCA RATON, Fla. — Caret Pharma plans to acquire the Fiber Choice dietary supplements brand from Moberg Pharma AB for $6.7 million.

The Caret Group subsidiary said Monday that Fiber Choice natural prebiotic fiber supplements will be marketed by IM HealthScience LLC, a company unit specializing in nonprescription products for the dietary management of digestive disorders.

Caret noted that the acquisition comes during a growth period for IM HealthScience that’s being driven by strong medical and consumer acceptance of its medical foods IBgard for irritable bowel syndrome)and FDgard (for functional dyspepsia).

Fiber Choice will be an important addition to the company’s digestive health product portfolio, according to Fred Hassan, chairman of Caret Group. A former chairman and chief executive officer of Pharmacia and of Schering-Plough, Hassan founded Caret Group earlier this year.

“We are pleased to welcome Fiber Choice to our family of companies. In a time of consumer empowerment and rising health care costs, people are taking a more active role in managing their own health and wellness,” Hassan stated. “We believe Fiber Choice offers these consumers and their health care providers an important option.”

Stockholm, Sweden-based Moberg said the divestment of Fiber Choice will enable the company to better focus resources on its core businesses.

Moberg had acquired Fiber Choice and the PediaCare, New Skin and Dermoplast brands in June 2016 Prestige Brands Inc. However, the key objective in the $40 million deal was to add the New Skin and Dermoplast specialty skin care brands, Moberg noted. PediaCare was divested this past December.

Fiber Choice tallied net sales of $7.1 million under the nearly one-year ownership by Moberg. The transaction with Caret Pharma is slated to close within the next four weeks.

“We are pleased with the agreement with Caret Pharma LLC, which enables us to increase focus on the core Moberg Pharma portfolio,” commented Peter Wolpert, chief executive officer of Moberg Pharma. “We have now successfully divested both noncore brands included in the acquisition from Prestige Brands, while the acquired strategic brands are developing well.”


Comments are closed.